Mrs Sharon Palmer, | |
134 Louise Rd, New Castle, DE 19720-1722 | |
(267) 928-0126 | |
Not Available |
Full Name | Mrs Sharon Palmer |
---|---|
Gender | Female |
Speciality | Counselor - Mental Health |
Location | 134 Louise Rd, New Castle, Delaware |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1326628348 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225XM0800X | Occupational Therapist - Mental Health | (* (Not Available)) | Secondary |
101YM0800X | Counselor - Mental Health | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Sharon Palmer, 134 Louise Rd, New Castle, DE 19720-1722 Ph: () - | Mrs Sharon Palmer, 134 Louise Rd, New Castle, DE 19720-1722 Ph: (267) 928-0126 |
News Archive
Atrial fibrillation patients with a prior history of stroke who undergo catheter ablation to treat the abnormal heart rhythm lower their long-term risk of a recurrent stroke by 50 percent, according to new research from the Intermountain Medical Center Heart Institute.
Killing microorganisms has become a national obsession. A pair of antimicrobial compounds known as triclosan and triclocarban are lately the weapons of choice in our war of attrition against the microbial world. Both chemicals are found in an array of personal care products like antimicrobial soaps, and triclosan also is formulated into everyday items ranging from plastics and toys to articles of clothing.
The Texas Tribune reports on politics surrounding rural health care in Texas in a three part series: "Politically speaking, it's no time to be an advocate for rural health care. In the last House Speaker's race and on the state's health care regulatory boards, rural lawmakers say they've been outnumbered and under-represented.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present new pre-clinical data on its oncology compound RX-3117 during a poster session at the American Association for Cancer Research (AACR) 103rd Annual Meeting being held in Chicago, Illinois, March 31 - April 4, 2012, at the McCormick Place Convention Center.
› Verified 9 days ago